Press Releases Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
17.23 ^USD	+5.25%		-2.43%	-16.36%

02-04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI

Press Releases

02-05	Neurogene to Participate in Upcoming Investor Conferences	BU
02-04	Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	BU
01-14	Neurogene : 2026 JP Morgan Presentation	PU
01-12	Neurogene : Corporate Presentation January 2026	PU
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome	BU
01-05	Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference	BU
12-04	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
11-13	Neurogene : 202511 NGNE Corporate Presentation	PU
11-13	Neurogene: Q3 Earnings Snapshot	AQ
11-13	Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates	BU
11-12	Neurogene : NGN 401 2H25 Update FINAL	PU
11-12	Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome	BU
11-06	Neurogene : 202511 NGNE Corporate Presentation FINAL	PU
11-06	Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome	BU
11-05	Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	BU
09/10/25	Neurogene : ESGCT 2025 HLH Combined vFinal Print	PU
09/10/25	Neurogene : 202510 NGNE Corporate Presentation FINAL	PU
09/10/25	Neurogene : Poster ESGCT2025 RoA Final Print	PU
09/10/25	Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025	BU
08/10/25	Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference	BU
06/10/25	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635c4	AQ
06/10/25	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
03/10/25	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05/09/25	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
12/08/25	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 8, 2025	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Press Releases

Filters